Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.74 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.74 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.74 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.74 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.71 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.69 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.69 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846586 | 1.00 | SLC28A1 (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2444841 | 0.90 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL6053985 | 0.90 | SLC28A1 (0.74) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14199627 | 0.88 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14178408 | 0.88 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL1054387 | 0.88 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL566229 | 0.88 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL3498224 | 0.88 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL6369206 | 0.88 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL7618891 | 0.88 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064822-A2 | CELLS AND METHODS FOR ENGINEERING CELLS WITH PERSISTENT TRANSGENE EXPRESSION | FACTOR BIOSCIENCE INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-119569589-A | Cationic lipids and uses thereof | 菲克特生物科学股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-114450265-B | Cationic lipids and uses thereof | 菲克特生物科学股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| EP-4419716-A1 | CANCER NEOANTIGENS | CureVac Netherlands B.V. (NL) | 2024-08-28 | — | — | EP | disclosed |
| EP-4373506-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR PREPARATION, AND USES | AGS Therapeutics SAS (FR) | 2024-05-29 | — | — | EP | disclosed |
| US-20240156987-A1 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | FACTOR BIOSCIENCE INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2023001894-A9 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR PREPARATION, AND USES | AGS THERAPEUTICS SAS (FR) | 2024-03-28 | — | — | WO | disclosed |
| EP-4320237-A1 | OLIGONUCLEOTIDES | Hudson Institute of Medical Research (AU) | 2024-02-14 | — | — | EP | disclosed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116115629-A | Nucleic acid products and methods of administration thereof | 菲克特生物科学股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-2379719-A1 | IMPROVED ISOTHERMAL STRAND DISPLACEMENT AMPLIFICATION | Human Genetic Signatures Pty Ltd (AU) | 2011-10-26 | — | — | EP | disclosed |
| US-7794928-B2 | Norovirus detection, methods and compositions therefor | WASHINGTON UNIVERSITY (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100221785-A1 | Isothermal Strand Displacement Amplification Using Primers Containing a Non-Regular Base | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2010-09-02 | — | — | US | disclosed |
| WO-2010083561-A1 | IMPROVED ISOTHERMAL STRAND DISPLACEMENT AMPLIFICATION | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2010-07-29 | — | — | WO | disclosed |
| EP-1883707-A4 | ISOTHERMAL STRAND DISPLACEMENT AMPLIFICATION USING PRIMERS CONTAINING A NON-REGULAR BASE | HUMAN GENETIC SIGNATURES PTY (AU) | 2009-08-05 | — | — | EP | disclosed |
| US-20080254443-A1 | Norovirus detection, methods and compositions therefor | WASHINGTON UNIVERSITY | 2008-10-16 | — | — | US | disclosed |
| EP-1883707-A1 | ISOTHERMAL STRAND DISPLACEMENT AMPLIFICATION USING PRIMERS CONTAINING A NON-REGULAR BASE | Human Genetic Signatures PTY Ltd (AU) | 2008-02-06 | — | — | EP | disclosed |
| WO-2006125267-A1 | ISOTHERMAL STRAND DISPLACEMENT AMPLIFICATION USING PRIMERS CONTAINING A NON-REGULAR BASE | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2006-11-30 | — | — | WO | disclosed |
| US-20060003957-A1 | RNA virus expression and replication, methods and uses therefor | WASHINGTON UNIVERSITY IN ST. LOUIS | 2006-01-05 | — | — | US | disclosed |
| WO-2000071105-A2 | TRICLOROACETIC ACID FOR THE PREPARATION OF SOLUTIONS AND/OR COMPOSITIONS FOR THE TREATMENT OF EROSIVE AND/OR ULCERATIVE LESIONS | MEZZOLI GIORGIO (IT) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156987-A1 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | STING1, MITF, RARA | SLC28A1 747/4885SLC28A2 628/4885SLC29A1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.